Research on circulating biomarkers, such as NfL, miRNA, and TDP-43, in blood shows significant promise in aiding the early diagnosis and prognosis of ALS, offering potential tools to differentiate ALS from other neurodegenerative conditions and better understand disease progression. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.